Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer

[1]  Jianjun Yu,et al.  Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer , 2020, EBioMedicine.

[2]  C. Ohyama,et al.  Serum N-glycan profiling is a potential biomarker for castration-resistant prostate cancer , 2019, Scientific Reports.

[3]  U. Testa,et al.  Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications , 2019, Medicines.

[4]  M. Nykter,et al.  Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer. , 2018, Cancer discovery.

[5]  M. Nykter,et al.  Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer , 2017, Journal of the National Cancer Institute.

[6]  T. Yamasaki,et al.  Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy‐naïve castration‐resistant prostate cancer: The Kyoto‐Baltimore collaboration , 2017, International journal of urology : official journal of the Japanese Urological Association.

[7]  D. Amadori,et al.  Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Matti Nykter,et al.  Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. , 2016, JAMA oncology.

[9]  Sean R. Landman,et al.  Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer , 2016, Nature Communications.

[10]  Li Ding,et al.  Protein-structure-guided discovery of functional mutations across 19 cancer types , 2016, Nature Genetics.

[11]  Keith A. Boroevich,et al.  Systematic analysis of mutation distribution in three dimensional protein structures identifies cancer driver genes , 2016, Scientific Reports.

[12]  C. Collins,et al.  Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients , 2016, Genome Biology.

[13]  V. Arora,et al.  Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer , 2015, Nature Reviews Cancer.

[14]  Delila Gasi Tandefelt,et al.  Plasma AR and abiraterone-resistant prostate cancer , 2015, Science Translational Medicine.

[15]  F. Saad,et al.  Treatment of mCRPC in the AR-axis-targeted therapy-resistant state. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  David C. Smith,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[17]  D. Amadori,et al.  Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone , 2015, British Journal of Cancer.

[18]  Martin E. Gleave,et al.  Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer , 2015, Clinical Cancer Research.

[19]  W. Isaacs,et al.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.

[20]  F. Saad,et al.  Enzalutamide in metastatic prostate cancer before chemotherapy. , 2014, The New England journal of medicine.

[21]  Gang Shao,et al.  A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. , 2013, Cancer discovery.

[22]  Joshua M. Korn,et al.  An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). , 2013, Cancer discovery.

[23]  O. Ogawa,et al.  Experimental Evidence of Persistent Androgen-Receptor-Dependency in Castration-Resistant Prostate Cancer , 2013, International journal of molecular sciences.

[24]  M. Rubin,et al.  Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. , 2013, European urology.

[25]  Alan Ashworth,et al.  Noninvasive Detection of HER2 Amplification with Plasma DNA Digital PCR , 2013, Clinical Cancer Research.

[26]  F. Saad,et al.  Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The New England journal of medicine.

[27]  S. Dhanasekaran,et al.  Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. , 2009, Cancer research.

[28]  H. Scher,et al.  Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.

[29]  L. Collette.  Re: Design and endpoints of clinical trials in patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, European urology.

[30]  Susan Halabi,et al.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  T. Golub,et al.  Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. , 2006, Cancer research.

[32]  R. Vessella,et al.  Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.